Xbrane Biopharma AB Total Liabilities

Latest as of June 2026: Skr103.76 Million SEK ≈ $11.17 Million USD

Xbrane Biopharma AB total liabilities. Based on the latest financial reports, Xbrane Biopharma AB (XBRANE) has total liabilities worth Skr103.76 Million SEK (≈ $11.17 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Xbrane Biopharma AB's assets to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Xbrane Biopharma AB (2012–2025)

Total liabilities of Xbrane Biopharma AB from 2012 to 2025. This chart illustrates how Xbrane Biopharma AB's total liabilities have evolved over time, based on quarterly financial data.

Xbrane Biopharma AB Competitors by Total Liabilities

The table below lists competitors of Xbrane Biopharma AB ranked by their total liabilities.

Company	Country	Total Liabilities
Imperial Equities Inc. V:IEI	Canada	CA$126.14 Million
Cpt Drives & Power Pcl BK:CPT	Thailand	฿549.96 Million
Wiseway Group Ltd AU:WWG	Australia	AU$59.81 Million
Numulae Gestion de Servicios SOCIMI SA MC:YNUM	Spain	€21.51 Million
3D Energi Ltd AU:TDO	Australia	AU$462.05K
Ensari Deri Gida Sanayi ve Ticaret AS IS:ENSRI	Turkey	TL770.87 Million
Monks Investment Trust PLC LSE:MNKS	UK	GBX239.37 Million

Liability Composition Analysis (2012–2025)

This chart breaks down Xbrane Biopharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Xbrane Biopharma AB asset portfolio.

Liquidity & Leverage Metrics

Xbrane Biopharma AB Total Liabilities Ratios Explained

Xbrane Biopharma AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	3.19	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.19	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.16	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Xbrane Biopharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Xbrane Biopharma AB (2012–2025)

The table below shows the annual total liabilities of Xbrane Biopharma AB from 2012 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr110.97 Million ≈ $11.94 Million	-82.49%
2024-12-31	Skr633.89 Million ≈ $68.22 Million	+31.47%
2023-12-31	Skr482.17 Million ≈ $51.89 Million	+81.52%
2022-12-31	Skr265.63 Million ≈ $28.59 Million	+3.48%
2021-12-31	Skr256.69 Million ≈ $27.62 Million	+24.57%
2020-12-31	Skr206.06 Million ≈ $22.17 Million	+33.27%
2019-12-31	Skr154.62 Million ≈ $16.64 Million	-8.95%
2018-12-31	Skr169.81 Million ≈ $18.27 Million	+652.89%
2017-12-31	Skr22.55 Million ≈ $2.43 Million	+108.67%
2016-12-31	Skr10.81 Million ≈ $1.16 Million	-61.15%
2015-12-31	Skr27.82 Million ≈ $2.99 Million	+7020.88%
2014-12-31	Skr390.70K ≈ $42.05K	-22.70%
2013-12-31	Skr505.44K ≈ $54.39K	-11.15%
2012-12-31	Skr568.90K ≈ $61.22K	--

About Xbrane Biopharma AB

ST:XBRANE Sweden Biotechnology

Market Cap

$29.71 Million

Skr276.11 Million SEK

Market Cap Rank

#23626 Global

#449 in Sweden

Share Price

Skr13.40

Change (1 day)

+1.90%

52-Week Range

Skr5.66 - Skr17.40

All Time High

Skr176.00